文献速递肿瘤 PET/CT

基线18F-FDG PET/CT代谢参数在伯基特淋巴瘤中的预后作用

Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-10-02

该研究回顾性纳入65例伯基特淋巴瘤患者,分析基线18F-FDG PET/CT代谢参数对治疗反应和预后的预测价值。中位随访40个月,中位PFS和OS分别为34和39个月。MTV和TLG是PFS和OS的独立预后因素,且与治疗结束时的治疗反应显著相关。

要点

  • MTV和TLG是伯基特淋巴瘤PFS和OS的独立预后因素。
  • 治疗结束时部分缓解组MTV和TLG显著高于完全缓解组, interim无显著差异。
  • SUVbw、SUVlbm、SUVbsa、L-L SUV R和L-BP SUV R与生存结局无关。

核心结论

  • 代谢肿瘤特征(MTV和TLG)与伯基特淋巴瘤的治疗反应和长期结局显著相关。
  • MTV和TLG被证实是PFS和OS的独立预后因素。
  • SUVbw、SUVlbm、SUVbsa、L-L SUV R和L-BP SUV R与结局生存无关。

研究设计与样本

  • 回顾性纳入65例接受基线、中期和治疗结束18F-FDG-PET/CT的伯基特淋巴瘤患者。
  • PET图像通过视觉和半定量分析测量SUVbw、SUVlbm、SUVbsa、L-L SUV R、L-BP SUV R、tMTV和TLG。
  • 采用Kaplan-Meier法绘制生存曲线。

主要发现

  • 中位随访40个月,中位PFS为34个月,中位OS为39个月。
  • 治疗结束时部分缓解组MTV和TLG显著高于完全缓解组,中期无显著差异。
  • 其他代谢PET/CT参数与治疗反应无关。
  • MTV和TLG是PFS和OS的独立预后因素。

关键数值与推荐

  • 中位随访40个月,中位PFS 34个月,中位OS 39个月。
  • 治疗结束时部分缓解组MTV和TLG显著高于完全缓解组,中期无显著差异。

临床怎么用

  • 基线18F-FDG PET/CT的MTV和TLG可能有助于预测伯基特淋巴瘤的治疗反应和长期结局。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Burkitt's lymphoma (BL) is an aggressive lymphoma subtype with high 18F-FDG avidity at 18F-FDG-PET/CT, but no validated criteria for PET/CT in treatment evaluation or prediction of outcome in BL are available. The aim of our study was to investigate whether the metabolic baseline PET/CT parameters can predict treatment response and prognosis in BL. MATERIALS AND METHODS: We retrospectively enrolled 65 patients who underwent baseline 18F-FDG-PET/CT, interim and end of treatment PET/CT. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value body weight (SUVbw), the maximum standardized uptake value lean body mass (SUVlbm), the maximum standardized uptake value body surface area (SUVbsa), lesion to liver SUVmax ratio (L-L SUV R), lesion to blood-pool SUVmax ratio (L-BP SUV R), total metabolic tumor volume (tMTV) and total lesion glycolysis (TLG). Survival curves were plotted according to the Kaplan-Meier method. RESULTS: At a median follow-up of 40 months, the median PFS and OS were 34 and 39 months. MTV and TLG were significantly higher in patients with partial response compared to complete response group at end of treatment, while no significant differences were found at interim. Other metabolic PET/CT parameters were not related to treatment response. MTV and TLG were demonstrated to be independent prognostic factors for both PFS and OS; instead SUVbw, SUVlbm, SUVbsa, L-L SUV R and L-BP SUV R were not related to outcome survival. CONCLUSIONS: Metabolic tumour features (MTV and TLG) were significantly correlated with response to treatment and long-term outcome.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Albano D, Bosio G, Pagani C, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging. 2018. PMID: 30276438. doi:10.1007/s00259-018-4173-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。